ITCI Intra-Cellular Therapies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ITCI

Price (delayed)

$43.06

Market cap

$3.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.04

Enterprise value

$3.41B

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this ...

Highlights
The revenue has grown by 48% from the previous quarter
The gross profit has grown by 47% from the previous quarter
The equity has increased by 46% year-on-year but it has declined by 10% since the previous quarter
ITCI's quick ratio is down by 28% from the previous quarter but it is up by 11% YoY
The net income is down by 27% YoY and by 2.2% from the previous quarter
ITCI's gross margin is down by 3% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intracellulartherapies.com
Peers: MNOV AGTC CRIS XNCR

Key stats

What are the main financial stats of ITCI
Market
Shares outstanding
81.34M
Market cap
$3.5B
Enterprise value
$3.41B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.32
Price to sales (P/S)
62.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.12
Earnings
Revenue
$55.75M
EBIT
-$237.33M
EBITDA
-$236.83M
Free cash flow
-$239.17M
Per share
EPS
-$3.04
Free cash flow per share
-$2.94
Book value per share
$6.82
Revenue per share
$0.69
TBVPS
$7.7
Balance sheet
Total assets
$625.7M
Total liabilities
$72.11M
Debt
$27.28M
Equity
$553.59M
Working capital
$550.88M
Liquidity
Debt to equity
0.05
Current ratio
11.93
Quick ratio
11.33
Net debt/EBITDA
0.4
Margins
EBITDA margin
-424.8%
Gross margin
90.7%
Net margin
-425.8%
Operating margin
-429.8%
Efficiency
Return on assets
-34%
Return on equity
-37.5%
Return on invested capital
-44.8%
Return on capital employed
-41.3%
Return on sales
-425.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITCI stock price

How has the Intra-Cellular Therapies stock price performed over time
Intraday
-0.16%
1 week
3.29%
1 month
17.17%
1 year
64.98%
YTD
35.41%
QTD
15.5%

Financial performance

How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$55.75M
Gross profit
$50.56M
Operating income
-$239.63M
Net income
-$237.37M
Gross margin
90.7%
Net margin
-425.8%
The net margin has surged by 93% year-on-year and by 31% since the previous quarter
The operating margin has soared by 93% YoY and by 31% from the previous quarter
The revenue has grown by 48% from the previous quarter
The gross profit has grown by 47% from the previous quarter

Growth

What is Intra-Cellular Therapies's growth rate over time

Valuation

What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
6.32
P/S
62.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.12
The EPS has grown by 3.5% from the previous quarter
ITCI's P/B is 98% above its 5-year quarterly average of 3.2 and 50% above its last 4 quarters average of 4.2
The equity has increased by 46% year-on-year but it has declined by 10% since the previous quarter
The revenue has grown by 48% from the previous quarter
The stock's price to sales (P/S) is 38% less than its last 4 quarters average of 100.5

Efficiency

How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 93% YoY and by 31% from the previous quarter
ITCI's return on invested capital is up by 47% year-on-year and by 7% since the previous quarter
The ROE has grown by 38% YoY and by 4.8% from the previous quarter
Intra-Cellular Therapies's ROA has increased by 34% YoY and by 4.8% from the previous quarter

Dividends

What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITCI.

Financial health

How did Intra-Cellular Therapies financials performed over time
Intra-Cellular Therapies's total assets has increased by 42% YoY but it has decreased by 7% from the previous quarter
ITCI's quick ratio is down by 28% from the previous quarter but it is up by 11% YoY
The debt is 95% smaller than the equity
The equity has increased by 46% year-on-year but it has declined by 10% since the previous quarter
ITCI's debt to equity is down by 29% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.